SLC5A2 and hydrops fetalis: Sodium-glucose co-transporter 2 (SGLT2) inhibitors have been used to reduce blood sugar in type 2 diabetes by increasing urinary glucose excretion.[5] Apart from diabetes,[6–8] large-scale randomized controlled trials (RCTs) have shown their efficacy in HF treatment, including the DAPA-HF, EMPEROR-Reduced, and SOLOIST-WHF trials.[9–11] Nevertheless, the heterogeneity among these studies may influence the interpretation of CV outcomes.